immune-mediated diseases
Novartis Expands Degrader-Focused Collaboration with Monte Rosa Through Major Molecular Glue Deal
Novartis; Monte Rosa Therapeutics; molecular glue degraders; MRT-6160; VAV1 protein; immune-mediated diseases; drug discovery; collaboration; milestone payments; AI/ML-enabled product engine
Tolerance Bio Secures $17.2M Seed Funding to Develop Thymus-Targeted Cell Therapies
Tolerance Bio, cell therapy, thymus, immune-mediated diseases, seed funding, allogeneic iPSC-based therapy
Alumis Files for IPO to Fund Phase 3 Studies for Second-Generation TYK2 Inhibitor
Alumis, IPO, TYK2 inhibitor, Phase 3 studies, immune-mediated diseases, biotech, precision immunology